The role of <scp>NMDARs</scp> in the anesthetic and antidepressant effects of ketamine

Zhou, Liang; Duan, Jingjing

doi:10.1111/cns.14464

Cited by 4 publications

(2 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cascade results in enhanced regional activity of the excitation network, including changes in neuroplasticity, which leads to increased synaptogenesis and synaptic potentiation in the limbic system. Another study reported that ketamine’s antidepressive effect through the NMDARs is controversial [ 82 ]. The advantage of ketamine compared to other traditional antidepressants is its rapid antidepressive action (for several days) in patients with major depressive disorder (MDD).…”

Section: Depressionmentioning

confidence: 99%

Ketamine, an Old–New Drug: Uses and Abuses

Savić Vujović,

Jotić,

Medić

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Ketamine as an old–new drug has a variety of clinical implications. In the last 30 years, ketamine has become popular for acute use in humans. Ketamine in standard doses is principally utilized for the induction and maintenance of surgical procedures. Besides its use in anesthesia and analgesia, recent studies have shown that ketamine has found a place in the treatment of asthma, epilepsy, depression, bipolar affective disorders, alcohol and heroin addiction. Ketamine primarily functions as a noncompetitive antagonist targeting the N-methyl-D-aspartate (NMDA) receptor, but its mechanism of action is complex. It is generally regarded as safe, with low doses and short-term use typically not leading to significant adverse effects. Also, ketamine is known as a powerful psychostimulant. During the past decade, ketamine has been one of the commonly abused drugs.

show abstract

Section: Depressionmentioning

confidence: 99%

Ketamine, an Old–New Drug: Uses and Abuses

Savić Vujović,

Jotić,

Medić

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Numerous reviews in recent years have offered explanations of the role of NMDAR in depression (Amidfar et al, 2019;Hanson et al, 2023;Zhou and Duan, 2023). It is important to use novel methods to uncover underlying connections and trends given the abundance of research in this field.…”

Section: Introductionmentioning

confidence: 99%

A scientometric analysis of research on the role of NMDA receptor in the treatment of depression

Chen,

Wang,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundThere have been numerous studies on NMDA receptors as therapeutic targets for depression. However, so far, there has been no comprehensive scientometric analysis of this field. Thus, we conducted a scientometric analysis with the aim of better elucidating the research hotspots and future trends in this field.MethodsPublications on NMDAR in Depression between 2004 and 2023 were retrieved from the Web of Science Core Collection (WoSCC) database. Then, VOSviewer, CiteSpace, Scimago Graphica, and R-bibliometrix—were used for the scientometric analysis and visualization.Results5,092 qualified documents were identified to scientometric analysis. In the past 20 years, there has been an upward trend in the number of annual publications. The United States led the world in terms of international collaborations, publications, and citations. 15 main clusters were identified from the co-cited references analysis with notable modularity (Q-value = 0.7628) and silhouette scores (S-value = 0.9171). According to the keyword and co-cited references analysis, treatment-resistant depression ketamine (an NMDAR antagonist), oxidative stress, synaptic plasticity, neuroplasticity related downstream factors like brain-derived neurotrophic factor were the research hotspots in recent years.ConclusionAs the first scientometric analysis of NMDAR in Depression, this study shed light on the development, trends, and hotspots of research about NMDAR in Depression worldwide. The application and potential mechanisms of ketamine in the treatment of major depressive disorder (MDD) are still a hot research topic at present. However, the side effects of NMDAR antagonist like ketamine have prompted research on new rapid acting antidepressants.

show abstract